TOP line results from two recent phase 3 clinical trials showed Eli Lilly's once-daily GLP-1 tablet orforglipron delivered significant improvements in glycaemic control in patients with type 2 diabetes, further establishing its effectiveness in these patients.
The findings build on earlier studies demonstrating efficacy in T2D patients (PD 23 Jun), as well as meaningful weight loss and cardiometabolic improvements in patients without diabetes (PD 18 Sep), and has now recorded superior results against both placebo and active comparators.
"Lilly plans to submit orforglipron for the treatment of type 2 diabetes and also for the treatment of obesity to the Therapeutic Goods Administration (TGA) by the end of this year," a spokesperson for Eli Lilly said.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Oct 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Oct 25
